![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1542526
¼¼°èÀÇ AAV ¼öŹ °³¹ß ¹× Á¦Á¶ ±â°ü ½ÃÀå Á¶»ç º¸°í¼ : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2024-2032³â)Global AAV Contract Development And Manufacturing Organizations Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032 |
AAV ¼öŹ °³¹ß¡¤Á¦Á¶ ±â°ü ½ÃÀåÀÇ ¼¼°è ¼ö¿ä´Â 2023³â 6¾ï 8,398¸¸ ´Þ·¯¿¡¼ 2032³â¿¡´Â ¾à 29¾ï 9,921¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µÇ¸ç, Á¶»ç ±â°£ÀÎ 2024-2032³âÀÇ CAGRÀº 17.85%ÀÔ´Ï´Ù.
AAV(¾Æµ¥³ëºÎ¼öü ¹ÙÀÌ·¯½º) CDMO´Â AAV ±â¹Ý À¯ÀüÀÚ Ä¡·áÁ¦ÀÇ °³¹ß, Á¦Á¶ ¹× ½ÃÇèÀ» Àü¹®À¸·Î ÇÏ´Â ±â¾÷À¸·Î, AAV´Â ÀÛÀº Å©±âÀÇ ºñº´¿ø¼º ¹ÙÀÌ·¯½º·Î À¯ÀüÀÚ Ä¡·á¿¡¼ À¯ÀüÀÚ µµÀÔ º¤ÅÍ·Î ÀϹÝÀûÀ¸·Î »ç¿ëµË´Ï´Ù. AAV CDMO´Â °í°´°ú Çù·ÂÇÏ¿© ƯÁ¤ Ä¡·á ¿ëµµ¿¡ ¸Â°Ô AAV º¤Å͸¦ ¼³°èÇϰí ÃÖÀûÈÇÕ´Ï´Ù. ¶ÇÇÑ ¼¼Æ÷ÁÖ °³¹ß, º¤ÅÍ »ý»ê °øÁ¤ ÃÖÀûÈ, ÃÖÁ¾ Á¦Ç° Á¤Á¦ ¹× Ư¼º Æò°¡ µî AAV º¤ÅÍ »ý»ê °ü·Ã ¼ºñ½ºµµ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ AAV CDMO´Â ¿ª°¡, ¼øµµ, ¹«±Õ¼º, µ¿Àϼº Å×½ºÆ®¸¦ Æ÷ÇÔÇÏ¿© AAV º¤ÅÍÀÇ ¾ÈÀü¼º°ú À¯È¿¼ºÀ» º¸ÀåÇϱâ À§ÇØ ¾ö°ÝÇÑ Å×½ºÆ®¸¦ ¼öÇàÇÕ´Ï´Ù.
´õ ¸¹Àº À¯ÀüÀÚ Ä¡·á Á¦Ç°ÀÌ ÀÓ»ó ½ÂÀÎÀ» ¹ÞÀ¸¸é¼ À¯ÀüÀÚ Ä¡·á ½ÃÀåÀº ºü¸£°Ô ¼ºÀåÇϰí ÀÖÀ¸¸ç, AAV º¤ÅÍ´Â À¯ÀüÀÚ Ä¡·á Àü´ÞÀÇ ÀϹÝÀûÀÎ ¼±ÅÃÀ̸ç, À¯ÀüÀÚ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â AAV CDMO ½ÃÀåÀÇ ¼ºÀåÀ» ÁÖµµÇϰí ÀÖÀ¸¸ç, AAV º¤ÅÍ ±â¼úÀÇ ¹ßÀüÀº º¤ÅÍ »ý»ê °øÁ¤ÀÇ °³¼±, µµÀÔ È¿À², ¸é¿ª ¹ÝÀÀÀÇ °¨¼Ò¸¦ °¡Á®¿Ô½À´Ï´Ù, º¤ÅÍ »ý»ê °øÁ¤ÀÇ °³¼±, µµÀÔ È¿À²ÀÇ Çâ»ó, ¸é¿ª ¹ÝÀÀÀÇ °¨¼Ò·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº AAV º¤Å͸¦ À¯ÀüÀÚ Ä¡·á ¿ëµµ¿¡ ´õ¿í ¸Å·ÂÀûÀ¸·Î ¸¸µé¾î AAV CDMO ¼ºñ½º¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ÃÖ±Ù ¼ö³â°£ À¯ÀüÀÚ Ä¡·á ¿¬±¸¿¡ ´ëÇÑ ÀÚ±Ý Áö¿øÀÌ Å©°Ô Áõ°¡ÇßÀ¸¸ç, Á¤ºÎ ±â°ü, ¹Î°£ ÅõÀÚÀÚ, ºñ¿µ¸® ´Üü µîÀÌ À¯ÀüÀÚ Ä¡·á ½ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀÚ±Ý Á¶´ÞÀº »õ·Î¿î À¯ÀüÀÚ Ä¡·áÁ¦ °³¹ßÀ» ÃËÁøÇÏ¿© AAV CDMO ¼ºñ½º¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖÀ¸¸ç, FDA¿Í °°Àº ±ÔÁ¦±â°üÀº À¯ÀüÀÚ Ä¡·áÁ¦ °³¹ßÀ» ÁöÁöÇϰí À¯ÀüÀÚ Ä¡·áÁ¦ Á¦Ç°¿¡ ´ëÇÑ ½Å¼ÓÇÑ ½ÂÀÎ °æ·Î¸¦ µµÀÔÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±ÔÁ¦ ´ç±¹ÀÇ Áö¿øÀº AAV CDMO ½ÃÀåÀ» Æ÷ÇÔÇÑ À¯ÀüÀÚ Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ¸¹Àº »ý¸í°øÇÐ ±â¾÷ ¹× Á¦¾à»çµéÀº °í°¡ÀÇ ÀÚü ½Ã¼³¿¡ ÅõÀÚÇÏ´Â ´ë½Å Àü¹® CDMO¿¡ À¯ÀüÀÚ Ä¡·áÁ¦ »ý»êÀ» À§Å¹ÇÏ´Â °ÍÀ» ¼±ÅÃÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼·Î ÀÎÇØ À¯ÀüÀÚ Ä¡·áÁ¦ °³¹ß ¹× Á¦Á¶¸¦ Áö¿øÇÒ °æÇèÀÌ Ç³ºÎÇÑ ÆÄÆ®³Ê¸¦ ã´Â ±â¾÷ÀÌ ´Ã¾î³ª¸é¼ AAV CDMO ¼ºñ½º¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
Á¶»ç º¸°í¼´Â Porter's Five Forces ¸ðµ¨, ½ÃÀå ¸Å·Âµµ ºÐ¼®, ¹ë·ùüÀÎ ºÐ¼®À» ´Ù·ç°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÅøÀº »ê¾÷ ±¸Á¶¸¦ ¸íÈ®ÇÏ°Ô ÆÄ¾ÇÇÏ°í ¼¼°è ¼öÁØ¿¡¼ °æÀïÀÇ ¸Å·ÂÀ» Æò°¡ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ ÅøÀº AAV ¼öŹ °³¹ß ¹× Á¦Á¶ Á¶Á÷ ¼¼°è ½ÃÀå¿¡¼ °¢ ºÎ¹®À» Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖÀ¸¸ç, AAV ¼öŹ °³¹ß¡¤Á¦Á¶ ±â°ü »ê¾÷ÀÇ ¼ºÀå°ú Ãß¼¼´Â ÀÌ ¿¬±¸¿¡ ´ëÇÑ ÀüüÀûÀÎ Á¢±Ù ¹æ½ÄÀ» Á¦°øÇÕ´Ï´Ù.
AAV ¼öŹ °³¹ß¡¤Á¦Á¶ ±â°ü ½ÃÀå º¸°í¼ÀÇ ÀÌ ¼½¼Ç¿¡¼´Â ±¹°¡ ¹× Áö¿ª ¼öÁØÀÇ ºÎ¹®¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ µ¥ÀÌÅ͸¦ Á¦°øÇÏ¿© Àü·«°¡µéÀÌ °¢ Á¦Ç° ¶Ç´Â ¼ºñ½ºÀÇ Å¸±êÃþÀ» ½Äº°Çϰí ÇâÈÄ ±âȸ¸¦ ÆÄ¾ÇÇÏ´Â µ¥ µµ¿òÀ» ÁÙ °ÍÀÔ´Ï´Ù.
ÀÌ ¼½¼Ç¿¡¼´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ AAV ¼öŹ °³¹ß¡¤Á¦Á¶ ±â°ü ½ÃÀåÀÇ ÇöÀç ¹× ¹Ì·¡ ¼ö¿ä¸¦ °Á¶ÇÏ´Â Áö¿ª Àü¸ÁÀ» ´Ù·ì´Ï´Ù. ¶ÇÇÑ ÀÌ º¸°í¼´Â ¸ðµç ÁÖ¿ä Áö¿ªÀÇ °³º° ¿ëµµ¿¡ ´ëÇÑ ¼ö¿ä, ÃßÁ¤ ¹× ¿¹Ãø¿¡ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù.
Ä¿½ºÅÒ ¿ä°ÇÀÌ ÀÖ´Â °æ¿ì, ¹®ÀÇÇØÁֽñ⠹ٶø´Ï´Ù. ´ç»çÀÇ Á¶»çÆÀÀº °í°´ÀÇ ¿ä±¸¿¡ µû¶ó ¸ÂÃãÇü º¸°í¼¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.
The global demand for AAV Contract Development And Manufacturing Organizations Market is presumed to reach the market size of nearly USD 2999.21 Million by 2032 from USD 683.98 Million in 2023 with a CAGR of 17.85% under the study period 2024 - 2032.
AAV (adeno-associated virus) Contract Development and Manufacturing Organizations (CDMOs) are companies that specialize in the development, manufacturing, and testing of AAV-based gene therapies. AAV is a small, non-pathogenic virus that is commonly used as a vector for gene delivery in gene therapy. AAV CDMOs work with clients to design and optimize AAV vectors for specific therapeutic applications. They also provide services for the production of AAV vectors, including the development of cell lines, optimization of vector production processes, and purification and characterization of the final product. In addition, AAV CDMOs conduct rigorous testing of the AAV vectors to ensure safety and efficacy, including tests for potency, purity, sterility, and identity.
The market for gene therapies is expanding rapidly as more gene therapy products are approved for clinical use. AAV vectors are a popular choice for gene therapy delivery, and the increasing demand for gene therapies is driving growth in the AAV CDMO market. Advances in AAV vector technology have led to improved vector production processes, increased transduction efficiency, and reduced immune responses. These advances have made AAV vectors more attractive for gene therapy applications and have increased the demand for AAV CDMO services. The availability of funding for gene therapy research has increased significantly in recent years, with government agencies, private investors, and non-profit organizations all contributing to the gene therapy market growth. This funding is driving the development of new gene therapies, which in turn is increasing demand for AAV CDMO services. Regulatory agencies such as the FDA have shown support for the development of gene therapies and have implemented expedited approval pathways for gene therapy products. This regulatory support is helping to drive growth in the gene therapy market, including the AAV CDMO market. Many biotech and pharma companies are choosing to outsource their gene therapy manufacturing to specialized CDMOs rather than investing in expensive in-house facilities. This trend is increasing demand for AAV CDMO services as these companies seek out experienced partners to help them develop and manufacture their gene therapy products.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of AAV Contract Development And Manufacturing Organizations. The growth and trends of AAV Contract Development And Manufacturing Organizations industry provide a holistic approach to this study.
This section of the AAV Contract Development And Manufacturing Organizations market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
This section covers the regional outlook, which accentuates current and future demand for the AAV Contract Development And Manufacturing Organizations market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the AAV Contract Development And Manufacturing Organizations market include Thermo Fischer Scientific Inc., Creative Biogene, Catalent Inc., Charles River Laboratories International Inc., Danaher (Aldevron), Forge Biologics, Genezen, ViroCell Biologics, Merck KGaA, Viralgen, Biovian Oy, Esco Lifesciences (Esco Aster Pte. Ltd.), GenScript ProBio, Porton Advanced Solution Ltd, Ask Bio, Showa Denko, Takara Bio Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.